A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
Felipe Samaniego,Ahad A. Sadiq,Daruka Mahadevan,Michael Z. Koontz,Jose C. Villasboas,John M. Burke,Erin G Reid,Mohamad Cherry,Jason Melear,Victor Priego,Patrick Cobb,Elizabeth H. Cull,Paul Conkling,David Cosgrove,Lindsey E. Roeker,Donna Nguyen Haney,Jia Hu,Ranjeet Kumar Sinha,William G Rice,Rafael Bejar Blood（2022）
关键词
btk/flt3 inhibitor luxeptinib,b-cell
AI 理解论文
溯源树
样例
